Levosulpiride API

Levosulpiride API is a medication that is classified as a selective dopamine D2 receptor antagonist and a prokinetic agent. It is primarily used in the treatment of various gastrointestinal disorders and some psychiatric conditions.

Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.

Dopamine D₂ receptor antagonism is a principal pharmacological feature of levosulpiride. In gastrointestinal research, this activity provides a way to investigate dopamine-mediated inhibitory regulation of enteric neurotransmission and motility.

Levosulpiride's gastrointestinal activity involves more than D₂ antagonism. Research in isolated guinea-pig gastrointestinal tissues found that it enhanced electrically evoked excitatory neuromuscular transmission, with a contribution from 5-HT₄ receptors. The responses also involved acetylcholine and tachykinin release and their respective postsynaptic receptors.

Relevant research directions include:

• Neurotransmitter release from enteric neurons;
• Cholinergic neuromuscular transmission;
• The relative contributions of D₂ and 5-HT₄ activity;
• Differences among gastrointestinal regions.

Receptor-selective tools, electrical field stimulation, neural transmission blockade, and direct muscle stimulation can help distinguish these mechanisms.

Enhanced tissue contraction does not necessarily indicate direct stimulation of smooth muscle. It may result from increased neurotransmitter release at nerve terminals, requiring separate evaluation of neural and muscular effects.

A study using isolated human gastric fundus, antrum, and jejunum found that levosulpiride enhanced electrically evoked cholinergic contractions in the antrum and jejunum, but not in the fundus. Some spontaneous motor parameters also changed differently from electrically evoked responses.

Gastrointestinal symptoms are not determined solely by gastric emptying. Gastric distension perception, compliance, and visceral sensitivity may also contribute.

A small clinical study examined levosulpiride's effects on gastric tone and perception in patients with functional dyspepsia. It reported increased discomfort thresholds and symptom changes after chronic administration. These findings provide a basis for investigating sensory–motor interactions, although interpretation is limited by sample size and study design.

Levosulpiride has central antidopaminergic activity and should not be described as a pharmacological tool acting exclusively in the peripheral gastrointestinal system.

Primary clinical research and case series have documented levosulpiride-associated parkinsonism, tremor, and dyskinesia. These reports frequently involve selected clinic or referral populations; their case proportions cannot be interpreted as incidence rates among all exposed individuals.

Neurological and behavioral studies should monitor:

• Spontaneous activity and motor coordination;
• Muscle tone and slowed movement;
• Sedation and alertness;
• Changes during repeated exposure and after withdrawal;
• Plasma concentrations and, where relevant, brain exposure.

Altered motor performance can influence behavioral measures of cognition, anxiety, or pain. It should therefore be assessed as a potential confounding factor.

Levosulpiride's D₂ antagonism is also associated with prolactin-related effects. Official product information lists hyperprolactinemia, galactorrhea, amenorrhea, gynecomastia, and changes in libido. cima.aemps.es

This pharmacological feature supports investigation of relationships between dopamine signaling and pituitary endocrine function. However, prolactin responses should be evaluated separately from other pharmacological outcomes.

Suggested research measurements include:

• Prolactin concentration–time relationships;
• Differences between single and repeated exposure;
• Recovery after withdrawal;
• Effects of sex, age, and baseline hormonal status;
• Related reproductive endocrine endpoints where appropriate.

Increased prolactin alone cannot establish gastrointestinal prokinetic efficacy or brain receptor occupancy. Drug exposure and sensitivity differ across tissues.